# Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With Asthma

> **NCT00961155** · PHASE2 · UNKNOWN · sponsor: **Medical University of Lodz** · enrollment: 200 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** cyklezonid
- **DRUG:** montelukast sodium
- **DRUG:** placebo
- **DRUG:** formoterol 12 mcg twice daily

## Key facts

- **NCT ID:** NCT00961155
- **Lead sponsor:** Medical University of Lodz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-08
- **Primary completion:** 2013-12
- **Final completion:** 2014-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2013-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00961155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00961155, "Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With Asthma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00961155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*